Ibandronate: a clinical pharmacological and pharmacokinetic update.
about
Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosisEndocytotic uptake of zoledronic acid by tubular cells may explain its renal effects in cancer patients receiving high doses of the compoundA novel biomaterial for osteotropic drug nanocarriers: synthesis and biocompatibility evaluation of a PLGA-ALE conjugate.Bioequivalence study of two formulations of ibandronic acid 150-mg film-coated tablets in healthy volunteers under fasting conditions: a randomized, open-label, three-way, reference-replicated crossover study.Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension.Development of clinical utility of zoledronic acid and patient considerations in the treatment of osteoporosisIbandronate and ventricular arrhythmia risk.Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trialsEfficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet.Clinical utility of risedronate in postmenopausal osteoporosis: patient considerations with delayed-release formulationEfficacy and safety of ibandronate in the treatment of neoplastic bone disease.Evidence of sustained vertebral and nonvertebral antifracture efficacy with ibandronate therapy: a systematic review.Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis.Oral ibandronate: a less frequently administered therapeutic option for postmenopausal osteoporosis.Ibandronate: efficacy in the treatment of metastatic bone disease.Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy.The role of the bone microenvironment in skeletal metastasis.Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate markerThe optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties.Renal safety of intravenous bisphosphonates in the treatment of osteoporosis.Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal womenIntravenous ibandronate rapidly reduces pain, neurochemical indices of central sensitization, tumor burden, and skeletal destruction in a mouse model of bone cancer.Bilateral Femoral Neck Insufficiency Fractures after Use of a Long-term Anti-resorptive Drug Therapy for Osteoporosis: A Case ReportOnce-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.Vitamin D and ibandronate prevent cancellous bone loss associated with binge alcohol treatment in male ratsPainful prosthesis: approaching the patient with persistent pain following total hip and knee arthroplasty.Identification of novel bone-specific molecular targets of binge alcohol and ibandronate by transcriptome analysis.Quarterly intravenous ibandronate for postmenopausal osteoporosis.Osteoporosis treatment: why ibandronic acid?Ibandronate: A Review in Japanese Patients with Osteoporosis.Bisphosphonates and cancer: what opportunities from nanotechnology?Local application of an ibandronate/collagen sponge improves femoral fracture healing in ovariectomized rats.Comparative pharmacokinetics of two intravenous administration regimens of tiludronate in healthy adult horses and effects on the bone resorption marker CTX-1.Bisphosphonates, specific inhibitors of osteoclast function and a class of drugs for osteoporosis therapy.Capillary electrophoresis-electrochemiluminescence detection method for the analysis of ibandronate in drug formulations and human urine.Renal Safety and Pharmacokinetics of Ibandronate in Multiple Myeloma Patients With or Without Impaired Renal Function
P2860
Q24680238-F4733390-35AB-45B3-ADCC-9AB6001C4EC2Q28543939-38D5B07B-6746-40F4-84F3-2D7901802B7DQ33405612-B05FF7B1-CEAB-4CFF-8B90-C3A1B985F575Q33804749-AC07991B-D4B2-40E0-BD3C-136A2743AF54Q34041189-F2FB7AFB-5EA6-4488-9822-10E26EB921E1Q34042003-574D2409-AE34-4CF6-B9A5-F6CE3A2C2BC2Q34103789-ECB3EDAF-D053-4044-99C4-FC6086629B86Q35331699-6D0CDFBF-1A07-4804-967E-FE799CE1708EQ35644131-49825AA6-EEB2-4EF7-9B9C-A4D3F5E84251Q35905973-0770AB89-74A8-455D-88E5-CE196B00A681Q35925543-0DDFB312-F08D-4A20-B5C2-57B1A9600E6BQ36056975-77A67A3C-F355-417A-8BF6-41D89AC25481Q36162247-7CC7E116-2A59-4700-84B9-ED1253DE2BEBQ36283739-6C035CF8-F78D-4A82-90CD-CFBAB020AB91Q36429562-FEEB83F5-9505-4009-97C8-4A2E4C42F9F1Q36459422-825EF5B0-4753-48A3-B7AC-F42AD5A5FCBFQ36491430-7D39DC0E-EB94-40FD-903E-346CFFBCC372Q36606751-DF75B1AC-405F-4926-98AD-8DC0A5BEC4A7Q36761569-E8EEA19B-1FDF-4D2F-9171-6BA9070C0217Q36984235-7B3DB3E9-5DE6-4096-852A-ED31662CACA2Q37017272-6ADF8009-1447-425E-B7DC-32617C4F2525Q37089016-DF450859-C717-48B2-85FD-F7D7358F8A13Q37150038-9D7DF32A-726B-4EAF-B413-F728E55F9FC7Q37174299-598C48F6-0170-44E5-B9C8-45E7C14016E6Q37195835-1E465810-C48E-45D4-9255-DC3AFDDD31E2Q37230596-20C977C0-056D-4F3C-9F69-373E2D1030D8Q37309830-8BB142FF-EC56-4695-BC19-D383A96FC98CQ37346101-0AEF7096-A4C7-4E7E-AF94-6E8AABDE2D41Q38104738-E1805693-B202-4BFC-B959-5F1613C52063Q38750001-52D55B12-3891-498E-80CD-A47722137C72Q41829362-830C70AE-2262-4C05-A690-73C0B9BD0758Q43419291-F110DE0E-E8D8-4EAD-8BC6-268FD13FDE49Q46728028-037FA63B-47DA-42D0-A2DB-434C00BC3EA9Q51873934-4E73C778-327E-4D2D-835F-0E4BB27017D4Q53087174-7C0EBC04-4335-45ED-A231-3392A0388518Q56832283-698B2C33-812E-4603-AF55-5225FCFD9E9F
P2860
Ibandronate: a clinical pharmacological and pharmacokinetic update.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Ibandronate: a clinical pharmacological and pharmacokinetic update.
@ast
Ibandronate: a clinical pharmacological and pharmacokinetic update.
@en
type
label
Ibandronate: a clinical pharmacological and pharmacokinetic update.
@ast
Ibandronate: a clinical pharmacological and pharmacokinetic update.
@en
prefLabel
Ibandronate: a clinical pharmacological and pharmacokinetic update.
@ast
Ibandronate: a clinical pharmacological and pharmacokinetic update.
@en
P2093
P2860
P356
P1476
Ibandronate: a clinical pharmacological and pharmacokinetic update.
@en
P2093
Eric Worth
Frieder Bauss
Joanne Barrett
Solomon Epstein
P2860
P304
P356
10.1177/0091270004267594
P577
2004-09-01T00:00:00Z